Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Otlertuzumab + Bendamustine in Relapsed CLL
NCT01188681Phase 2Completed
- Sponsor
- Aptevo Therapeutics
- Start
- Sep 2010
- Primary completion
- Dec 2014
- Modality
- Monoclonal Antibodies
- Countries
- 5
01
Overview
A Phase 2 trial of Otlertuzumab in chronic lymphocytic leukemia (CLL), sponsored by Aptevo Therapeutics. Started Sep 2010; status: completed.
02
Drugs
Otlertuzumab
03
Conditions
chronic lymphocytic leukemia (CLL)
Beyond the preview
Go deeper on NCT01188681.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01188681.